Special Alerts:

[UPDATED 06/02/2011] FDA’s meta-analysis of 31 randomized controlled trials comparing Angiotensin Receptor Blockers (ARBs) to other treatment found no evidence of an increased risk of incident (new) cancer, cancer-related death, breast cancer, lung cancer, or prostate cancer in patients receiving ARBs. For more information visit the FDA website at: [Web] and [Web].